TY  - JOUR
A1  - Ruiz-Heredia, Yanira
A1  - Sánchez-Vega, Beatriz
A1  - Onecha, Esther
A1  - Barrio, Santiago
A1  - Alonso, Rafael
A1  - Carlos Martínez-Avila, Jose
A1  - Cuenca, Isabel
A1  - Agirre, Xabier
A1  - Braggio, Esteban
A1  - Hernández, Miguel-T.
A1  - Martínez, Rafael
A1  - Rosiñol, Laura
A1  - Gutierrez, Norma
A1  - Martin-Ramos, Marisa
A1  - Ocio, Enrique M.
A1  - Echeveste, María-Asunción
A1  - Pérez de Oteyza, Jaime
A1  - Oriol, Albert
A1  - Bargay, Joan
A1  - Gironella, Mercedes
A1  - Ayala, Rosa
A1  - Bladé, Joan
A1  - Mateos, María-Victoria
A1  - Kortum, Klaus M.
A1  - Stewart, Keith
A1  - García-Sanz, Ramón
A1  - San Miguel, Jesús
A1  - José Lahuerta, Juan
A1  - Martinez-Lopez, Joaquín
T1  - Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
JF  - Haematologica
N2  - no abstract available
KW  - Copy number changes
KW  - Survival
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227151
VL  - 103
IS  - 11
ER  - 
TY  - JOUR
A1  - Zhou, Xiang
A1  - Steinhardt, Maximilian J.
A1  - Grathwohl, Denise
A1  - Meckel, Katharina
A1  - Nickel, Katharina
A1  - Leicht, Hans‐Benno
A1  - Krummenast, Franziska
A1  - Einsele, Hermann
A1  - Rasche, Leo
A1  - Kortüm, Klaus M.
T1  - Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
JF  - Cancer Medicine
N2  - Background
Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in RRMM.


Methods
We retrospectively analyzed data of 56 patients with RRMM who received Pom‐PAD‐Dara between September 2016 and May 2019.


Results
Patients were heavily pretreated with a median of four prior lines of therapy, including autologous and allogenic stem cell transplant in 50 (89%) and six (11%) patients, respectively. The overall response rate (ORR) was 78% and we observed partial remission, very good partial remission, and complete remission in 27 (48%), 13 (23%) and four (7%) patients, respectively. Median progression‐free survival was 7 months (95% CI, 3.3‐10.7) and the median overall survival was not reached at 24 months. Adverse events grade ≥ 3 were observed 41 (73%) patients and included neutropenia (n = 28, 50%), anemia (n = 22, 39%), thrombocytopenia (n = 21, 38%), and pneumonia (n = 6, 11%).


Conclusion
Pom‐PAD‐Dara represents a promising multiagent regimen in heavily pretreated RRMM patients with high ORR and an acceptable safety profile.
KW  - multiple myeloma
KW  - Pom‐PAD‐Dara
KW  - refractory
KW  - relapse
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-218029
VL  - 9
IS  - 16
ER  -